



## ASX ANNOUNCEMENT

22 March 2021

### Investor webinar & Q&A

**Respiri Limited (ASX:RSH) ("Respiri" or the "Company")**, an eHealth SaaS Company supporting respiratory health management, today announces it will hold an investor webinar & Q&A for all shareholders and interested parties following the announcement regarding results of its application to the US FDA for market clearance of wheezo™.

The webinar will be hosted by CEO of Respiri Mr Marjan Mikel at 9:30am AEDT tomorrow, Tuesday 23 March 2021.

Please register for the webinar at: [https://us02web.zoom.us/webinar/register/WN\\_K5-5fFtYSz22NZP9INwE4A](https://us02web.zoom.us/webinar/register/WN_K5-5fFtYSz22NZP9INwE4A)

After registering, you will receive a confirmation email containing information about joining the webinar as well as dial-in details for those that would prefer to join by phone.

For the Q&A session, investors are invited to send questions prior to the webinar to [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

Please note a replay of the webinar will be available at the above-mentioned Zoom link shortly following the conclusion of the live session.

- ENDS -

For further information, investors and media please contact:

**Mr Marjan Mikel**  
CEO & Managing Director  
Respiri Limited  
P: +61 408 462 873  
E: [marjan@respiri.co](mailto:marjan@respiri.co)

**Mr Nicholas Smedley**  
Executive Chairman  
Respiri Limited  
P: +61 447 074 160  
E: [nicholas@respiri.co](mailto:nicholas@respiri.co)

™ wheezo is a trademark of Respiri Limited.

*This ASX announcement dated 22 March 2021 has been authorised for release by the Board of Directors of Respiri Limited.*

### About Respiri Limited

Respiri is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. wheezo, Respiri's innovative technology, comprises an eHealth app combined with a simple, easy to use, handheld device. wheezo is the first smart device to help improve asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management platform also facilitates the sharing of data with caregivers, physicians, and other health care professionals.

Respiri's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respiri Limited's operations are based in Melbourne, Australia.

For additional information about Respiri and its products, please visit [www.respiri.co](http://www.respiri.co)